We are live on ! Find out more
RVPHW

Reviva Pharmaceuticals Warrants
RVPHW

Delisted

RVPHW was delisted on the 12th of December, 2025.

Back to rankings

17 hedge funds and large institutions have $2.6M invested in Reviva Pharmaceuticals Warrants in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

6% more funds holding

Funds holding: 16 → 17 (+1)

1% less capital invested

Capital invested by funds: $2.62M → $2.6M (-$17K)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PAMP
Polar Asset Management Partners
Ontario, Canada
+$75.9K
2
CAC
Cowen and Company
New York
+$20.3K
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$2.75K
4
BCM
Basso Capital Management
Connecticut
+$275

Top Sellers

Rank Fund Capital Flow
1
PAM
Panagora Asset Management
Massachusetts
-$26.4K
2
HIM
HGC Investment Management
Ontario, Canada
-$20K
3
Walleye Trading
Walleye Trading
New York
-$1.03K
4
GCL
Glazer Capital LLC
New York
-$229
5
OAM
Oxford Asset Management
United Kingdom
-$229
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
1
Boothbay Fund Management
New York
$2.04M – – –
BCM
2
BlueCrest Capital Management
Jersey
$151K – – –
PAMP
3
Polar Asset Management Partners
Ontario, Canada
$93K +$75.9K +330,800 +827%
AA
4
AQR Arbitrage
Connecticut
$63K – – –
GCIA
5
Gabelli & Co Investment Advisers
New York
$49K – – –
6CM
6
683 Capital Management
New York
$36K – – –
OAM
7
Oxford Asset Management
United Kingdom
$32K -$229 -1,000 -0.5%
GF
8
Gabelli Funds
New York
$30K – – –
CAC
9
Cowen and Company
New York
$27K +$20.3K +88,600 +443%
GCL
10
Glazer Capital LLC
New York
$26K -$229 -1,000 -0.3%
Walleye Trading
11
Walleye Trading
New York
$20K -$1.03K -4,501 -2%
PC
12
Periscope Capital
Ontario, Canada
$16K – – –
BCM
13
Bluefin Capital Management
New York
$8K – – –
BI
14
Bulldog Investors
New Jersey
$5K – – –
Hudson Bay Capital Management
15
Hudson Bay Capital Management
Connecticut
$2K +$2.75K +12,000 New
PAM
16
Panagora Asset Management
Massachusetts
– -$26.4K -114,987 -99%
HIM
17
HGC Investment Management
Ontario, Canada
– -$20K -88,700 Closed
BCM
18
Basso Capital Management
Connecticut
– +$275 +1,200 New

RVPHW Hedge Fund Activity: Q4 2019 in Review

17 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q4 2019, worth a combined $2.6M — down 0.65% from $2.62M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new RVPHW positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.

The largest buyer was Polar Asset Management Partners, adding an estimated $75.9K. The largest seller was Panagora Asset Management, cutting an estimated $26.4K.

  • 17 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q4 2019, up from 16 in Q3 2019.
  • Funds reported $2.6M of Reviva Pharmaceuticals Warrants stock for Q4 2019, down 0.65% quarter-over-quarter.
  • 2 funds opened new Reviva Pharmaceuticals Warrants positions in Q4 2019 and 1 closed out, a net change of +1 holder.
  • The largest Reviva Pharmaceuticals Warrants buyer in Q4 2019 was Polar Asset Management Partners, an estimated $75.9K added.
  • The largest Reviva Pharmaceuticals Warrants seller in Q4 2019 was Panagora Asset Management, an estimated $26.4K sold.

Based on aggregated 13F filings for Q4 2019.